Transcatheter aortic valve replacement for oncology patients with severe symptomatic aortic stenosis: New hope for a complicated medical condition.
The clinical scenario of severe AS among patients with cancer diseases poses a growing clinical challenge. The current study indicates that patients with cancer and severe AS that underwent AVR (predominantly TAVR) survived longer than those without AVR, regardless of the cancer type or treatment. Patients can benefit from specialized management teams composed of cardiologists and oncologists that can navigate the crisis of severe symptomatic AS during oncology course.